QNCX
Quince Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.73
+8.07%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$1.39
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 14, 2026
- EPS actual
- -$12
- EPS estimate
- -$28
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +9.6%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $74
- PT range
- $70 – $82
- Analysts
- 5
5 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 14, 2026 | -$28 | -$12 | Beat 56.07% | — |
| May 11, 2026 | -$1.30 | -$0.59 | Beat 54.62% | — |
| Nov 12, 2025 | -$0.20 | -$0.25 | Miss -25.00% | — |
| Mar 24, 2025 | -$0.19 | -$0.28 | Miss -47.37% | — |
| Aug 13, 2024 | — | -$0.18 | — | — |
| Apr 1, 2024 | — | -$0.21 | — | — |
| Feb 14, 2024 | -$0.28 | -$0.22 | Beat 21.43% | $36.0K |
| Nov 14, 2023 | — | -$0.15 | — | — |
| Aug 3, 2023 | — | -$0.14 | — | — |
| May 15, 2023 | -$0.31 | -$0.34 | Miss -9.95% | — |
| Mar 15, 2023 | -$0.29 | -$0.13 | Beat 54.80% | — |
| Mar 1, 2022 | -$0.65 | -$0.78 | Miss -20.00% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026